Additionally, treatment strategies such as beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, along with risk factors like valvular heart disease, mitral regurgitation, and cardiomyopathy in pregnancy, demonstrated high APY(around 2022). This evidence concerns the gene NR3C2 and cardiomyopathy.